干扰素α-2b的耐受性，一种可能用于治疗活动性克罗恩病的新疗法。

Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease.

作者信息

Davidsen B, Munkholm P, Schlichting P, Nielsen O H, Krarup H, Bonnevie-Nielsen V

机构信息

Department of Medical Gastroenterology C. Herlev Hospital, University of Copenhagen, Denmark.

出版信息

Aliment Pharmacol Ther. 1995 Feb;9(1):75-9. doi: 10.1111/j.1365-2036.1995.tb00355.x.

DOI:10.1111/j.1365-2036.1995.tb00355.x

PMID:7766748

Abstract

BACKGROUND AND AIMS

Due to the need for new principles for the treatment of Crohn's disease and due to the documented immunomodulatory effects of interferon alpha, the tolerability and effect(s) of interferon alpha-2b (Introna) in active Crohn's disease were examined in a pilot study.

METHODS

Five patients with active Crohn's disease (activity index (CDAI) scores of 235-517), were treated with interferon alpha-2b for 12 weeks.

RESULTS

All patients tolerated the treatment, but developed influenza-like symptoms, which were fully controlled by paracetamol. Two patients obtained partial remission with a decline in activity index scores of 39% and 50%. The activity of 2',5'-oligoadenylate synthetase, which together with two other interferon-induced proteins, neopterin and beta 2-microglobulin were increased during treatment, indicated clearly an in vivo uptake of interferon. Sedimentation rate, C-reactive protein, orosomucoid, albumin, specific inflammatory markers: soluble interleukin-2 alpha-receptors (sIL-2R) and intercellular adhesion molecule-1 (ICAM-1) did not show any changes before or after treatment.

CONCLUSION

Future multicentre investigations are required to evaluate the clinical effect of interferon alpha-2b treatment in active Crohn's disease.

摘要

背景与目的

由于治疗克罗恩病需要新的原则，且已有文献记载干扰素α具有免疫调节作用，因此在一项初步研究中对干扰素α-2b（英特龙）治疗活动期克罗恩病的耐受性和效果进行了研究。

方法

5例活动期克罗恩病患者（活动指数（CDAI）评分235 - 517）接受干扰素α-2b治疗12周。

结果

所有患者均耐受治疗，但出现了流感样症状，对乙酰氨基酚可完全控制这些症状。2例患者获得部分缓解，活动指数评分分别下降了39%和50%。治疗期间，2',5'-寡腺苷酸合成酶以及另外两种干扰素诱导蛋白（新蝶呤和β2-微球蛋白）的活性增加，这清楚地表明体内摄取了干扰素。血沉、C反应蛋白、血清类黏蛋白、白蛋白、特异性炎症标志物：可溶性白细胞介素-2α受体（sIL-2R）和细胞间黏附分子-1（ICAM-1）在治疗前后均未显示任何变化。